Globalization, pharmaceutical pricing, and South African health policy: Managing confrontation with U.S. firms and politicians

International Journal of Health Services

Volumn 29, Issue 4, 1999, Pages 765-792

  Bond, Patrick ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; ESSENTIAL DRUG; ZALCITABINE; ZIDOVUDINE;

GLOBALIZATION; HEALTH POLICY; INTERNATIONAL RELATIONS; PHARMACEUTICAL INDUSTRY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG LEGISLATION; GOVERNMENT; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLITICS; REVIEW; SOUTH AFRICA; UNITED STATES;

CONFLICT (PSYCHOLOGY); DEMOCRACY; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; MARKETING OF HEALTH SERVICES; NEGOTIATING; POLITICS; POWER (PSYCHOLOGY); SOUTH AFRICA; UNITED STATES;

SOUTH AFRICA;

EID: 0032714926     PISSN: 00207314     EISSN: None     Source Type: Journal    
DOI: 10.2190/4MA6-53E3-LE1X-C1YY     Document Type: Review

References (56)

1. Bond, P., Pillay, Y. Gand Sanders, D. The state of neoliberalism in South Africa: Economic, social, and health transformation in question. Int. J. Health Serv. 27(1): 2540,1997.
2. Pillay, Y. Gand Bond, P. Health and social policies in the new South Africa. Int. J. Health Serv. 25(4): 727-743,1995.
3. Marais, H. South Africa: The Political Economy of Change. Zed, London, 1998.
4. Bond, P. Elite Transition: From Apartheid to Neoliberalism in South Africa. Pluto, London. 1999.
5. Republic of South Africa Department of Health. Annual Report. Pretoria, 1997.
6. Republic of South Africa Department of Health. Towards a National Health System. Pretoria, 1996.
7. Republic of South Africa. Medicines and Related Substances Control Amendment Act. Cape Town, 1997.
8. Love, J. Info-Policy-Notes: U.S. Law Requires U.S. Department of State to Seek Repeal of South African Law on Essential Medicines. Consumer Project on Technology, Washington, D.C., April 7,1999.
9. Richwine, L. U.S. blocking distribution of AIDS drugs, critics say. San Francisco Examiner, April 12,1999.
10. Navarro, V. The Poulies of Health Policy: The U.S. Reforms, 1980-1994. Blackwell, Oxford, 1994.
11. Love, J. Personal communication, Washington, D.C., April 16,1999.
12. Larkin, B. U.S. Government Efforts to Negotiate the Repeal, Termination or Withdrawal of Article 15(c) of the South African Medicines and Related Substances Act of 1997. U.S. Department of State Report Washington, D.C., February 5, 1999.
13. United States Congress. Omnibus Consolidated and Emergency Supplemental Appropriations Act, 1999 (H.R. 4328). Washington, D.C., October 21,1998.
14. Barber, S. Plan blunts long-term threat to U.S. aid for SA. Business Day, July 20,1998.
15. Mitchell, D. Compulsory Licensing of Anti-HIV Drugs Stirs Debate in Geneva. JAMA HIV/AIDS Health Information (internet version), April 1,1999.
16. Médecins sans Frontières, Health Action International, and Consumer Project on Technology. AIDS and Essential Medicines and Compulsory Licensing: Summary of the March 25-27, 1999, Geneva Meeting on Compulsory Licensing of Essential Medical Technologies. Geneva, April 9,1999.
17. United States Trade Representative. Special 301 Review. Washington, D.C., April 30, 1999.
18. Nader, R. Medicine held hostage by profits. San Francisco Bay Guardian, April 28, 1999.
19. Love, J. Gore/Mbeki Commission and Compulsory Licensing Disputes with South Africa. Personal communication, Washington, D.C., April 2,1999.
20. Richwine, L. Gore Worked to Soften South Africa Health Law. Reuters, Washington, D.C., April 16,1999.
21. Goozner, M. Third World battles for AIDS drugs. Chicago Tribune, April 28, 1999.
22. Stemberg, S. Victims lost in battle over drug patents. USA Today, May 24,1999.
23. Barber, S. U.S. withholds benefits overZuma's bill. Business Day, July 15,1998.
24. Pharmaceutical Research and Manufacturers of America. PhRMA Supports USTR on South Africa. Press release. Washington, D.C., April 30,1999.
25. Bale, H. IFPMA Position on Compulsory Licensing. E-mail communication to Treatment-access forum (treatment@CritPath.org). Geneva, April 15,1999.
26. Love, J. Who pays what in drug development Nature 397:202,1999.
27. Mitsuya, Het al. Credit government scientists with developing anti-AIDS drug. New York Times, September 28,1989.
28. Love, J. Statement on Bristol-Myers Squibb Announcement. Consumer Project on Technology, Washington, D.C., May 6,1999.
29. Pharmaceutical Research and Manufacturers of America. Submission for the "Special 301" Report on Intellectual Property Barriers. Washington, D.C., February 16,1999.
30. Bailey, H. Bitter pills: The battle over prescription drug prices. Center for Responsive Politics Money in Politics Alert 5(17), May 17,1999.
31. Navarro, V. The politics of health care reform in the United States, 1992-1994: A historical review. Int. J. Health Serv. 25(2): 185-201,1995.
32. Love, J. Washington DC as a Small Town. E-mail communication to IP-Health (ip-health@essential.org). Washington, D.C., April 13,1999.
33. Wemer, Dand Sanders, D. Questioning the Solution: The Politics of Primary Health Care and Child Survival. Health Wrights, Palo Alto, Calif., 1997.
34. Judis, J. K. Street Gore. The American Prospect 45, July-August, 1999.
35. Corn, D. Gore to South Africans: Drop dead. New York Press, June 2,1999.
36. Ridgeway, J. Gore AIDS scandal helps drug companies nix cheap medicines. Village Voice, June 2,1999.
37. Caelers, D. Gore Told to Ease up on Anti-South Africa Drugs War. Africa News Service, May 18,1999.
38. Kelly, E. Cost of Prescription Drugs Drives Consumers to Canada. Gannett News Service, May 21,1999.
39. Quaid, L. Lawmakers Push for Cheaper Prescriptions. Associated Press, May 28, 1999.
40. Wolfe, W. PDA head tells seniors agency can't help cut drug costs. Minneapolis Star Tribune, June 3,1999.
41. Sanders, B., Berry, Mand Emerson, J. A. Dear Colleague Letter: Help Americans Enjoy the Same Low Prescription Drug Prices as Other Countries. U.S. House of Representatives, Washington, D.C., May 25,1999.
42. Williams, F. Campaign over drug licensing to grow. Financial Times, March 29, 1999.
43. Russell, S. New crusade to lower AIDS drug costs. San Francisco Chronicle, May 24, 1999.
44. Silverman, M., Lydecker, Mand Lee, P. Bad Medicine. Stanford University Press, Palo Alto, Calif., 1992.
45. Bond, P. Mozambican parliament questions debt management Johannesburg Sunday Independent, December 20, 1998.
46. Orr, J. Rexall for profits. Dollars and Sense, 128, July-August 1987.
47. Assavanonda, A. NGOs rally against patent law changes: Call on US to stop pressuring Thailand. Bangkok Post, September 8,1998.
48. Bond, P. Global financial crisis: Why we should care, what we should do. Indicator SA 15(3), 1998.
49. Stiglitz, J. More Instruments and Broader Goals: Moving toward a Post-Washington Consensus. WIDER Annual Lecture, Helsinki, Finland, January 7,1998.
50. Bond, P. Moving toward-or beyond?-a 'Post-Washington Consensus on development. Indicator SA 15(4), 1998.
51. Galli, P. Investors wary of ANC two-thirds. Johannesburg Star Business Report, JuneS, 1999.
52. Arrighi, G., Hopkins, Tand Wallerstein, I. Anti-Systemic Movements. Verso, London, 1989.
53. Weisman, J. Activists doubt Gore tries to reduce cost of AIDS drugs: ACT-UP, candidate's staff talk on medicine in Africa. Baltimore Sun, June 23,1999.
54. Huffington, A. Pharmacologie Al. June 28,1999. Available from http/www.arianna online.com/columns/files/062899.html
55. Mr. Gore and the AIDS drugs (editorial). Washington Post, June 24,1999.
56. Gore, A. Letter to James E. Clybum, Black Congressional Caucus, June 25,1999.